AU2206801A - Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate - Google Patents

Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate

Info

Publication number
AU2206801A
AU2206801A AU22068/01A AU2206801A AU2206801A AU 2206801 A AU2206801 A AU 2206801A AU 22068/01 A AU22068/01 A AU 22068/01A AU 2206801 A AU2206801 A AU 2206801A AU 2206801 A AU2206801 A AU 2206801A
Authority
AU
Australia
Prior art keywords
salmeterol
fluticasone propionate
aerosol formulation
pharmaceutical aerosol
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU22068/01A
Other languages
English (en)
Inventor
Alan Leslie Cripps
Paul Johnson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9930878.5A external-priority patent/GB9930878D0/en
Priority claimed from GB0018686A external-priority patent/GB0018686D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU2206801A publication Critical patent/AU2206801A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU22068/01A 1999-12-24 2000-12-21 Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate Abandoned AU2206801A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9930878.5A GB9930878D0 (en) 1999-12-24 1999-12-24 Pharmaceutical formulation
GB9930878 1999-12-24
GB0018686 2000-07-28
GB0018686A GB0018686D0 (en) 2000-07-28 2000-07-28 Pharmaceutical formulation
PCT/GB2000/004939 WO2001047493A1 (en) 1999-12-24 2000-12-21 Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate

Publications (1)

Publication Number Publication Date
AU2206801A true AU2206801A (en) 2001-07-09

Family

ID=26244762

Family Applications (1)

Application Number Title Priority Date Filing Date
AU22068/01A Abandoned AU2206801A (en) 1999-12-24 2000-12-21 Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate

Country Status (8)

Country Link
US (1) US20030032632A1 (enExample)
EP (1) EP1248597B1 (enExample)
JP (1) JP2003518484A (enExample)
AT (1) ATE291898T1 (enExample)
AU (1) AU2206801A (enExample)
DE (1) DE60019167T2 (enExample)
ES (1) ES2238334T3 (enExample)
WO (1) WO2001047493A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
IT1313553B1 (it) 1999-07-23 2002-09-09 Chiesi Farma Spa Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
WO2001037805A1 (en) * 1999-11-23 2001-05-31 Glaxo Group Limited Pharmaceutical formulations of salmeterol
US20050048001A1 (en) * 1999-11-23 2005-03-03 Cripps Alan Leslie Pharmaceutical formulations of salmeterol
IT1317846B1 (it) 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
US20060257324A1 (en) 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
CN1213732C (zh) 2000-05-22 2005-08-10 奇斯药制品公司 用于加压计量吸入器的稳定药用溶液制剂
GB2367011A (en) * 2000-08-26 2002-03-27 Glaxo Group Ltd Metered dose inhaler for salmeterol
AR030516A1 (es) * 2000-08-31 2003-08-20 Glaxo Group Ltd Uso de una combinacion de salmeterol y fluticasona
GB0021927D0 (en) * 2000-09-07 2000-10-25 Glaxo Group Ltd Use of pharmaceutical combination
GB0105560D0 (en) * 2001-03-07 2001-04-25 Glaxo Group Ltd Pharmaceutical formulations
GB0106031D0 (en) * 2001-03-12 2001-05-02 Glaxo Group Ltd Use
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
CA2469435A1 (en) 2001-12-21 2003-07-24 X-Ceptor Therapeutics, Inc. Modulators of lxr
EP1415647A1 (en) * 2002-10-23 2004-05-06 CHIESI FARMACEUTICI S.p.A. "Long-acting beta-2 agonists ultrafine formulations"
CA2495875C (en) * 2002-08-27 2010-06-22 Schering Corporation Process for producing metered dose inhaler formulations
EP1595531A1 (en) 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
AU2005293328B2 (en) * 2004-10-12 2010-09-30 Generics (Uk) Limited Process for the preparation of suspension aerosol formulations, wherein the particles are formed by precipitation inside an aerosol canister
US7680778B2 (en) * 2007-01-19 2010-03-16 Microsoft Corporation Support for reverse and stemmed hit-highlighting
GB0712454D0 (en) * 2007-06-27 2007-08-08 Generics Uk Ltd Pharmaceutical compositions
WO2011145109A1 (en) * 2010-05-20 2011-11-24 Sun Pharma Advanced Research Company Ltd., Dry powder inhalation composition
TWI399202B (zh) * 2011-03-17 2013-06-21 Intech Biopharm Ltd 製備用於治療呼吸道疾病之定量噴霧吸入劑的製程方法
US9241904B1 (en) 2011-08-19 2016-01-26 Intech Biopharm Ltd. Method for preparing metered dose sprayed inhaler for treating respiratory disease
CN102379846B (zh) * 2011-10-21 2014-07-02 江苏长风药业有限公司 以氢氟烷烃和聚乙二醇为辅料氟替卡松丙酸酯气雾剂制剂
JP6285419B2 (ja) 2012-05-08 2018-02-28 ニコックス アフサァルミィクス、 インコーポレイテッドＮｉｃｏｘ Ｏｐｈｔｈａｌｍｉｃｓ， Ｉｎｃ． 疎水性治療剤の調製物、製造方法およびその使用
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
US9815865B2 (en) 2013-01-07 2017-11-14 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
US11554229B2 (en) 2013-03-26 2023-01-17 OptiNose Inc. Nasal administration
RU2016152090A (ru) * 2014-06-25 2018-07-27 Оптиноуз Ас Интраназальное введение
WO2016018892A1 (en) 2014-07-29 2016-02-04 3M Innovative Properties Company Method of preparing a pharmaceutical composition
CN114712338A (zh) 2016-09-19 2022-07-08 墨西哥氟石股份公司 药物组合物
ES2877575T3 (es) * 2016-09-19 2021-11-17 Mexichem Fluor Sa De Cv Composición farmacéutica que comprende salmeterol
ES2891579T3 (es) 2016-09-19 2022-01-28 Mexichem Fluor Sa De Cv Composición farmacéutica
US20240238309A1 (en) * 2020-03-25 2024-07-18 Insmed Incorporated Pharmaceutical formulations of treprostinil prodrugs and methods of use thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL289785A (enExample) * 1962-11-29
CH634480A5 (de) * 1977-11-25 1983-02-15 Schwarzkopf Gmbh Hans Unter druck stehendes aerosolpraeparat.
IL95590A (en) * 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
US5919827A (en) * 1990-07-11 1999-07-06 Sepracor Inc. Method for treating asthma using optically pure R(-) salmeterol
CA2094266C (en) * 1990-10-18 1999-06-01 Robert K. Schultz Aerosol formulations of beclomethasone-17,21-dipropionate
MX9203481A (es) * 1990-10-18 1992-07-01 Minnesota Mining & Mfg Formulaciones.
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
US5683676A (en) * 1991-12-12 1997-11-04 Glaxo Group Limited Canister containing aerosol formulations containing P134a and particulate medicaments
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
JP3009924B2 (ja) * 1992-12-09 2000-02-14 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 安定化医用エアーゾル溶液製剤
DE4446891A1 (de) * 1994-12-27 1996-07-04 Falk Pharma Gmbh Stabile wäßrige Budesonid-Lösung
JP2001505171A (ja) * 1996-12-04 2001-04-17 バイオグラン アイルランド（アール アンド ディ）リミテッド 製薬組成物及びその投与のための装置
WO1998034595A1 (de) * 1997-02-05 1998-08-13 Jago Research Ag Medizinische aerosolformulierungen
GB2326334A (en) * 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
GB2332372B (en) * 1997-12-08 2002-08-14 Minnesota Mining & Mfg Pharmaceutical aerosol compositions
GB9808802D0 (en) * 1998-04-24 1998-06-24 Glaxo Group Ltd Pharmaceutical formulations
ME00838B (me) * 1998-06-18 2008-09-29 Boehringer Ingelheim Pharmaceuticals Inc Farmaceutske formulacije za aerosolove sa dve ili više aktivnih supstanci
US6241969B1 (en) * 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
US6231519B1 (en) * 1999-05-04 2001-05-15 Nokia Corporation Method and apparatus for providing air quality analysis based on human reactions and clustering methods
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
FR2798290B1 (fr) * 1999-09-11 2003-09-12 Glaxo Group Ltd Formulation pharmaceutique de propionate de fluticasone
HK1054232A1 (zh) * 2000-01-31 2003-11-21 辉瑞产品公司 用作pde4同工酶抑制剂的嘧啶甲酰胺

Also Published As

Publication number Publication date
DE60019167D1 (de) 2005-05-04
ES2238334T3 (es) 2005-09-01
DE60019167T2 (de) 2006-05-11
EP1248597B1 (en) 2005-03-30
EP1248597A1 (en) 2002-10-16
WO2001047493A1 (en) 2001-07-05
ATE291898T1 (de) 2005-04-15
US20030032632A1 (en) 2003-02-13
JP2003518484A (ja) 2003-06-10

Similar Documents

Publication Publication Date Title
AU2206801A (en) Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate
EP1143930B8 (en) Pharmaceutical formulation of fluticasone propionate
AU2003244450A1 (en) Formulations for inhalation
GB2332372B (en) Pharmaceutical aerosol compositions
HK1042444A1 (zh) 藥用噴霧製劑
NZ298169A (en) Aerosol drug formulation; comprises hydrofluoroalkane propellant, medicament for inhalation and a surfactant
CA2416403A1 (en) A medicinal aerosol formulation
CA2111002A1 (en) Non-Chlorofluorocarbon Aerosol Formulations
MY126768A (en) Combinations of formoterol and fluticasone propionate for asthma
EP1277467A3 (en) Non-chlorofluorocarbon aerosol formulations
AU3038197A (en) Aerosol formulations
WO2004000290A8 (en) Pharmaceutical composition
GB0016876D0 (en) Novel formulation
AU2003293593A1 (en) Pharmaceutical preparations, use of said preparations and method for increasing the bioavailability of medicaments for peroral administration
MXPA03001752A (es) Uso de la combinacion de salmeterol y propionato de fluticasona.
AU1534501A (en) Pharmaceutical formulations of salmeterol
WO2002007672A3 (en) A medicinal aerosol formulation
CA2376847A1 (en) Complex of eletriptan and a cyclodextrin derivative
CA2446562A1 (en) Pharmaceutical formulation of fluticasone propionate
WO2002041875A3 (de) Verfahren zur herstellung leicht löslicher arzneimittelformulierungen und entsprechende formulierungen
HK1056997A (en) Pharmaceutical formulation of salmeterol and fluticasone propionate
MX9707238A (es) Formulaciones en aerosol de butixocort.

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase